

Katexco Pharmaceuticals To Develop Cannabis Derivative CBD to Suppress Inflammatory Conditions

Posted on [October 25, 2018](#)



Dr. Rothbard

MedicalResearch.com Interview with:
Jonathan Rothbard, MA, PhD
Steinman Lab Stanford Medicine
Co-founder [Katexco Pharmaceuticals](#)

MedicalResearch.com: *What is the background for this new company? How did Katexco get its name?*

Response: Researchers with Stanford University, Jonathan Rothbard and Lawrence Steinman, formed Katexco Pharmaceuticals. Katexco will focus on developing oral therapies for inflammatory diseases based on cannabis and nicotine receptors.

Katexco will work to develop the first drug to focus on a key receptor on immune cells that are involved in inflammatory disease. The first primary target indications include gastrointestinal disorders like Crohn's disease, gout and multiple sclerosis.

Katexco is from the Greek word to restrain or regulate, and we are trying to restrain the immune system in inflammatory disease.

MedicalResearch.com: *How is Katexco using the cannabis derivative CBD to develop treatments for inflammatory disorders?*

Response: Medical marijuana has been proven effective for the treatment of inflammatory and autoimmune diseases. Behind that is the endocannabinoid system, lipid-based retrograde neurotransmitters that bind to cannabinoid receptors. Cannabinoid receptor proteins are expressed throughout the mammalian central nervous system, including the brain, and the peripheral nervous

system, and these receptors are also found on immune cells outside the nervous system. (see citation below)

Katexco plans to harness the properties of the endocannabinoid system and the nicotine receptor system (nAChRs), which respond to the neurotransmitter acetylcholine

MedicalResearch.com: What should readers take away from your report?

Response: Katexco plans to harness the properties of the endocannabinoid system and the nicotine receptor system (nAChRs), which respond to the neurotransmitter acetylcholine.

Citation:

Emerging Role of the CB2 Cannabinoid Receptor in Immune Regulation and Therapeutic Prospects
G. A. Cabral* and L. Griffin-Thomas Department of Microbiology and Immunology, Virginia Commonwealth University, School of Medicine, Richmond, Virginia, 23298, USA

Expert Rev Mol Med. ; 11: e3. doi:10.1017/S1462399409000957.

<https://medicalresearch.com/author-interviews/katexco-pharmaceuticals-to-develop-cannabis-derivative-cbd-to-suppress-inflammatory-conditions/45470/>